Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 55NETWORK 2INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cyclophosphamide 388Specimen Handling 376Magnetic Resonance Spectroscopy 328Radiotherapy 306Biopsy 273Cisplatin 258Carboplatin 255Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 183Bevacizumab 181Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 141Taxes 127Docetaxel 122Chemotherapy, Adjuvant 114Oxaliplatin 113fludarabine phosphate 111Methotrexate 108Rituximab 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Protons × Clear all
NCT04671667 2026-05-08

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
188 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡